3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
14
Burkitt Lymphoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lung Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Smoldering Multiple Myeloma
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Mantle-Cell
2
Immunoglobulin Light-chain Amyloidosis
2
Down Syndrome
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Prostatic Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Plasma Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Hodgkin Disease
1
Fatigue
1
Esophageal Neoplasms
1
Brain Neoplasms
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Blast Crisis
1
Ann Arbor Stage II Mantle Cell Lymphoma
1
Interventions
Magnetic Resonance Spectroscopy
49
enzalutamide
46
apalutamide
36
Specimen Handling
34
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
27
Prednisone
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
20
Radiotherapy
19
Biopsy
17
Leuprolide
15
relugolix
11
gallium 68 PSMA-11
11
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
Standard of Care
10
Nivolumab
10
cabazitaxel
9
X-Rays
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
dexamethasone acetate
×
90 days
×
Clear all
NCT06136598
2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1
Completed
14 enrolled